SLU-PP-332 is a next-generation small molecule known for its potent activation of REV-ERBα and REV-ERBβ nuclear receptors, key modulators of circadian rhythm, metabolic function, and inflammatory responses. By influencing these pathways, SLU-PP-332 plays a crucial role in regulating gene expression related to lipid and glucose metabolism, mitochondrial biogenesis, and immune modulation.
Potential Applications: Weight Management & Obesity Research: Supports increased energy expenditure and fat metabolism, making it a promising candidate for studies related to obesity and metabolic syndrome. Type 2 Diabetes & Insulin Resistance: Enhances glucose homeostasis and may improve insulin sensitivity by regulating circadian genes tied to glucose metabolism.
Non-Alcoholic Fatty Liver Disease (NAFLD): Potential to reduce hepatic lipid accumulation and improve liver function markers through REV-ERB activation. Mitochondrial Health & Energy Production: Stimulates mitochondrial biogenesis and oxidative capacity, contributing to cellular energy efficiency. Circadian Rhythm Disorders: Could be explored in research related to sleep disturbances, jet lag, and shift work disorder, given its circadian rhythm regulatory effects.
Neuroinflammation & Cognitive Function: Emerging studies suggest its role in modulating neuroinflammatory pathways, with potential links to cognitive health and neurodegenerative conditions. Preclinical data indicates that SLU-PP-332 may help address various metabolic and inflammatory conditions by synchronizing circadian and metabolic cycles.
BOTTLE DESIGN MAY VARY SLU-PP-223 COA.
Summary of published preclinical and clinical literature, provided for research context only. Not a claim of efficacy and not medical advice.
